Undisclosed TDP-43 inhibitor / Dewpoint Therap, Mitsubishi Tanabe - LARVOL DELTA

Mitsubishi Tanabe Pharma America to Present Research on ALS Pathology at the 2025 ALS Drug Development Summit (PRNewswire) - "Mitsubishi Tanabe Pharma America, Inc...today announced that preclinical research exploring key mechanisms underlying amyotrophic lateral sclerosis (ALS) pathology will be presented at the 2025 ALS Drug Development Summit being held in Boston, Massachusetts, May 12-14....The presentation will feature findings from preclinical research examining the effects of LRSAM1 in mitigating TDP-43 pathophysiology by promoting the degradation of the cytotoxic C-terminal fragments of TDP-43 iPSC-derived neurons from a patient with ALS. These findings support the advancement of therapeutic strategies targeting TDP-43 pathology and neuronal toxicity in ALS."

Preclinical • Amyotrophic Lateral Sclerosis

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS (GlobeNewswire) - "Dewpoint Therapeutics Inc...announced today that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1st, 2024. Under the terms of the agreement, Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives, with a total nominal deal value of up to $480M. Upon reaching these milestones, MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization. Dewpoint will also receive tiered royalties on net sales."

Licensing / partnership • Amyotrophic Lateral Sclerosis